EntryPoint Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

EntryPoint Capital’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,503	Closed	-$87.6K	–	1011
2024 Q2	$87.6K	Sell	8,503 -10,877	-56%	-$112K	0.13%	364
2024 Q1	$206K	Buy	+19,380	New	+$165K	0.18%	109

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

EntryPoint Capital's PHAT Position: Q3 2024 in Review

EntryPoint Capital sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 8,503 shares — an estimated $87.6K sold.

EntryPoint Capital first reported a position in PHAT in Q1 2024 and held it in 2 quarters. The position peaked at $206K in Q1 2024. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

EntryPoint Capital reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
EntryPoint Capital sold 8,503 Phathom Pharmaceuticals shares in Q3 2024, an estimated $87.6K.
EntryPoint Capital first reported a position in Phathom Pharmaceuticals in Q1 2024 and held it in 2 quarters.
EntryPoint Capital's Phathom Pharmaceuticals position peaked at $206K in Q1 2024.
133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.